Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Recombinant human parathyroid hormone [rhPTH(1-84)] represents a new class of anabolic agents for the treatment of osteoporosis.

AUC0-10 = (268.87 ± 47.72), (538.93 ± 146.89) and (1364.11 ± 176.82) pg hr/mL; (197.20 ± 50.78), (207.15 ± 72.08) and (344.05 ± 77.06) pg hr/mL, respectively. t1/2 = (2.34 ± 1.93), (2.58 ± 1.18) and (2.74 ± 1.31) hr; (3.37 ± 1.82), (4.39 ± 3.79), and (3.99 ± 1.85) hr, respectively.

Who Took Part

According to the abstract, 32 volunteers were involved.

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Area Under Curve, Asian People, Body Mass Index, Calcium, Healthy Volunteers, Parathyroid Hormone and Phosphates.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in 32 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2012 (Basic & clinical pharmacology & toxicology), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.